We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.
The company provided clear near‑term regulatory, clinical and financial guidance: a Type B pre‑NDA meeting (in‑person; briefing book submitted after an April 2026 request) is scheduled for mid‑June 2026 and the NDA submission target remains September 2026 (pathway: one adequate and well‑controlled study + confirmatory evidence from PROSERA and TORREY), with a potential approval in Q3 2027 if the meeting proceeds as expected; clinically, PROSERA showed a placebo‑adjusted 6‑minute walk distance benefit of 13.3 m at week 24 (seralutinib +28.2 m vs placebo +13.5 m; p=0.032, did not meet prespecified alpha 0.025), all four key secondaries favored seralutinib, a stronger effect was seen in a prespecified risk‑enriched subgroup, and the CT FRI substudy enrolled 162 patients with 125 evaluable paired scans at week 24 showing statistically significant multi‑compartment arterial, venous, fibrosis‑like and complexity remodeling signals; financially, cash and marketable securities totaled $99M as of March 31, 2026 with runway to Q1 2027, the company has cut operating expenses (including a reduction in force affecting ~50% of staff) and proposes a convertible note exchange that would reduce convertible debt from $200M to $72M (a $128M reduction), extend maturity to 2030, issue new secured notes bearing 7.5% cash interest paid semiannually secured by a first‑priority lien, and requires minimum 98% participation (may be waived).
PROSERA Phase III showed a placebo-adjusted improvement of 13.3 meters in 6-minute walk distance (6MWD) at week 24: seralutinib improved 28.2 m from baseline vs 13.5 m for placebo (p = 0.032). The result met the traditional 0.05 significance threshold.
All four key secondary endpoints favored seralutinib over placebo, with a stronger effect observed in the prespecified risk-enriched subgroup, supporting consistency across clinical measures.
162 patients enrolled in the prespecified CT FRI substudy with 125 evaluable paired baseline and week-24 scans. Results showed multi-compartment structural reverse remodeling (arterial, venous, fibrosis-like parenchymal and vascular complexity parameters) that correlated with clinical endpoints (6MWD, NT-proBNP, REVEAL Lite 2). Notable findings included statistically significant reductions in large arterial blood volume proportion (BV10A) and reductions in fibrosis-like parenchymal volume, and increases in total venous blood volume and venous branching.
FDA granted an in-person Type B pre-NDA meeting (briefing book submitted) scheduled for mid-June. Company is targeting an NDA submission in September 2026 and, if process proceeds as expected, a potential approval in Q3 2027.
Agreement terms would reduce outstanding convertible debt from $200 million to $72 million (a $128 million reduction, ~64% decrease) on a fully subscribed basis, extend maturity from 2027 to 2030, and issue new secured convertible notes bearing 7.5% cash interest (paid semiannually). Early tender incentives include equity consideration and warrants.
Company implemented rapid cost stewardship actions (including a targeted reduction in force and pausing non-essential development) to preserve runway and focus resources on NDA submission and potential commercialization.
Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer Bio Q1 2026 Earnings Call. [Operator Instructions] It is now my pleasure to turn the call over to Bryan Giraudo, Chief Operating Officer and Chief Financial Officer. Please go ahead.
Good morning, and thank you for joining us. Before we begin, I'd like to remind listeners that today's discussion includes forward-looking statements, including statements regarding our regulatory plans, potential NDA submission and approval timing, commercialization, expectations, cash runway, capital structure and the potential therapeutic benefit and future developments of seralutinib. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and today's press release for discussions of these risks. We undertake no obligation to update these forward-looking statements, except as required by law. We are very excited this morning to have on our call today, Faheem Hasnain, Caryn Peterson, Dr. Rob Roscigno. Additionally, we have Dr.
Jean-Marie Bruey, Dr. Rainer Zimmermann, Dr. Megan Flynn, Dr. Robin Osterhout; and Bob Smith, our Chief Commercial Officer, to speak about our exciting results this morning. Today, we plan to cover 3 topics: First, a regulatory update, including our Type B pre-NDA meeting; Secondly, we will discuss results from our PROSERA CT FRI substudy; and third, an update on our capital structure, including the convertible note exchange. Our fina...